Replies to post #103545 on Biotech Values

[genisi]

FDA panel unanimously recommend approval for FRX' ceftaroline in the CABP and cSSSI indications.

http://finance.yahoo.com/news/FDA-Advisory-Committee-bw-2542658315.html?x=0&.v=1

[DewDiligence]

FDA approves FRX’s Teflaro (ceftaroline) for CAP and skin infections:

http://www.reuters.com/article/idCNN2915765720101029

The approval makes good on FRX’s 2006 acquisition of Cerexa for $480M (#msg-15557243).